928 related articles for article (PubMed ID: 24508508)
1. Rapamycin: one drug, many effects.
Li J; Kim SG; Blenis J
Cell Metab; 2014 Mar; 19(3):373-9. PubMed ID: 24508508
[TBL] [Abstract][Full Text] [Related]
2. Mammalian target of rapamycin (mTOR) pathways in neurological diseases.
Wong M
Biomed J; 2013; 36(2):40-50. PubMed ID: 23644232
[TBL] [Abstract][Full Text] [Related]
3. mTOR activation is a biomarker and a central pathway to autoimmune disorders, cancer, obesity, and aging.
Perl A
Ann N Y Acad Sci; 2015 Jun; 1346(1):33-44. PubMed ID: 25907074
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of the Mechanistic Target of Rapamycin (mTOR)-Rapamycin and Beyond.
Lamming DW
Cold Spring Harb Perspect Med; 2016 May; 6(5):. PubMed ID: 27048303
[TBL] [Abstract][Full Text] [Related]
5. Mammalian target of rapamycin: a central node of complex signaling cascades.
Dobashi Y; Watanabe Y; Miwa C; Suzuki S; Koyama S
Int J Clin Exp Pathol; 2011 Jun; 4(5):476-95. PubMed ID: 21738819
[TBL] [Abstract][Full Text] [Related]
6. Longevity, aging and rapamycin.
Ehninger D; Neff F; Xie K
Cell Mol Life Sci; 2014 Nov; 71(22):4325-46. PubMed ID: 25015322
[TBL] [Abstract][Full Text] [Related]
7. mTOR Inhibitors in Children: Current Indications and Future Directions in Neurology.
Jeong A; Wong M
Curr Neurol Neurosci Rep; 2016 Dec; 16(12):102. PubMed ID: 27815691
[TBL] [Abstract][Full Text] [Related]
8. mTOR signaling in growth control and disease.
Laplante M; Sabatini DM
Cell; 2012 Apr; 149(2):274-93. PubMed ID: 22500797
[TBL] [Abstract][Full Text] [Related]
9. Next Generation Strategies for Geroprotection via mTORC1 Inhibition.
Dumas SN; Lamming DW
J Gerontol A Biol Sci Med Sci; 2020 Jan; 75(1):14-23. PubMed ID: 30794726
[TBL] [Abstract][Full Text] [Related]
10. Rapalogs and mTOR inhibitors as anti-aging therapeutics.
Lamming DW; Ye L; Sabatini DM; Baur JA
J Clin Invest; 2013 Mar; 123(3):980-9. PubMed ID: 23454761
[TBL] [Abstract][Full Text] [Related]
11. Rapamycin passes the torch: a new generation of mTOR inhibitors.
Benjamin D; Colombi M; Moroni C; Hall MN
Nat Rev Drug Discov; 2011 Oct; 10(11):868-80. PubMed ID: 22037041
[TBL] [Abstract][Full Text] [Related]
12. Chronic mTOR inhibition in mice with rapamycin alters T, B, myeloid, and innate lymphoid cells and gut flora and prolongs life of immune-deficient mice.
Hurez V; Dao V; Liu A; Pandeswara S; Gelfond J; Sun L; Bergman M; Orihuela CJ; Galvan V; Padrón Á; Drerup J; Liu Y; Hasty P; Sharp ZD; Curiel TJ
Aging Cell; 2015 Dec; 14(6):945-56. PubMed ID: 26315673
[TBL] [Abstract][Full Text] [Related]
13. The Enigma of Rapamycin Dosage.
Mukhopadhyay S; Frias MA; Chatterjee A; Yellen P; Foster DA
Mol Cancer Ther; 2016 Mar; 15(3):347-53. PubMed ID: 26916116
[TBL] [Abstract][Full Text] [Related]
14. Recent clinical trials of mTOR-targeted cancer therapies.
Don AS; Zheng XF
Rev Recent Clin Trials; 2011 Jan; 6(1):24-35. PubMed ID: 20868343
[TBL] [Abstract][Full Text] [Related]
15. mTOR in health and in sickness.
Liko D; Hall MN
J Mol Med (Berl); 2015 Oct; 93(10):1061-73. PubMed ID: 26391637
[TBL] [Abstract][Full Text] [Related]
16. Rapamycin extends life- and health span because it slows aging.
Blagosklonny MV
Aging (Albany NY); 2013 Aug; 5(8):592-8. PubMed ID: 23934728
[TBL] [Abstract][Full Text] [Related]
17. mTOR: Its Critical Role in Metabolic Diseases, Cancer, and the Aging Process.
Marafie SK; Al-Mulla F; Abubaker J
Int J Mol Sci; 2024 Jun; 25(11):. PubMed ID: 38892329
[TBL] [Abstract][Full Text] [Related]
18. mTOR pathway inhibitors in cancer therapy: moving past rapamycin.
Wacheck V
Pharmacogenomics; 2010 Sep; 11(9):1189-91. PubMed ID: 20860456
[No Abstract] [Full Text] [Related]
19. mTOR in aging, metabolism, and cancer.
Cornu M; Albert V; Hall MN
Curr Opin Genet Dev; 2013 Feb; 23(1):53-62. PubMed ID: 23317514
[TBL] [Abstract][Full Text] [Related]
20. Targeting mTOR signaling pathway in ovarian cancer.
Mabuchi S; Hisamatsu T; Kimura T
Curr Med Chem; 2011; 18(19):2960-8. PubMed ID: 21651485
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
